Head-To-Head Comparison: Bullfrog AI (NASDAQ:BFRG) versus HeartBeam (NASDAQ:BEAT)

Bullfrog AI (NASDAQ:BFRG) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Bullfrog AI and HeartBeam, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	0	0	0	1.00
HeartBeam	1	2	4	1	2.63

HeartBeam has a consensus price target of $4.83, suggesting a potential upside of 425.08%. Given HeartBeam’s stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Bullfrog AI.

Profitability

This table compares Bullfrog AI and HeartBeam’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
HeartBeam	N/A	-1,034.04%	-434.40%

Earnings & Valuation

This table compares Bullfrog AI and HeartBeam”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120,000.00	70.16	-$6.50 million	($0.54)	-1.23
HeartBeam	N/A	N/A	-$21.01 million	($0.56)	-1.64

Bullfrog AI has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bullfrog AI has a beta of -3, meaning that its stock price is 400% less volatile than the S&P 500. Comparatively, HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.

Insider and Institutional Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 25.2% of Bullfrog AI shares are held by insiders. Comparatively, 18.0% of HeartBeam shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Bullfrog AI beats HeartBeam on 7 of the 13 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.